The scientist’s investigation covers issues in Immunology, Transplantation, Internal medicine, T cell and Antigen. His biological study spans a wide range of topics, including Melanoma, Stem cell and DNA sequencing. His research investigates the connection between Transplantation and topics such as Leukemia that intersect with issues in Bone marrow, Myeloid leukemia, Chemotherapy and Monoclonal antibody therapy.
His biological study deals with issues like Oncology, which deal with fields such as Allogeneic transplantation and Metastasis. Karl S. Peggs usually deals with T cell and limits it to topics linked to CD8 and Interferon. His studies deal with areas such as Cancer research, Virology, Tumor microenvironment, Molecular biology and Transduction as well as Antigen.
Karl S. Peggs mainly focuses on Immunology, Transplantation, Internal medicine, Hematopoietic stem cell transplantation and Alemtuzumab. T cell, Immune system, Immunotherapy, Antigen and CD8 are among the areas of Immunology where the researcher is concentrating his efforts. His Transplantation study combines topics from a wide range of disciplines, such as Stem cell and Lymphoma.
His Internal medicine research integrates issues from Gastroenterology, Surgery and Oncology. His Hematopoietic stem cell transplantation research is multidisciplinary, incorporating perspectives in Transplantation Conditioning, Donor Lymphocytes and Intensive care medicine. His Alemtuzumab research is multidisciplinary, relying on both Fludarabine and Cohort.
Karl S. Peggs focuses on Cancer research, Transplantation, Internal medicine, Oncology and Immunology. His studies in Transplantation integrate themes in fields like Congenital cytomegalovirus infection, Clinical trial and Stem cell. His research ties Gastroenterology and Internal medicine together.
The various areas that Karl S. Peggs examines in his Oncology study include T cell, Mantle cell lymphoma and Rituximab. His Immunology study frequently draws connections between adjacent fields such as Lung cancer. Karl S. Peggs has researched Alemtuzumab in several fields, including Hematopoietic stem cell transplantation, Immunosuppression and Adoptive cell transfer.
Karl S. Peggs mostly deals with Transplantation, Cancer research, Internal medicine, Hematopoietic stem cell transplantation and Immunity. The Cancer research study combines topics in areas such as Relapsed refractory, B cell and CD19. His research links Oncology with Internal medicine.
Karl S. Peggs combines subjects such as Gastroenterology, Vitamin D and neurology, Salvage therapy and Intensive care medicine with his study of Hematopoietic stem cell transplantation. His Immunity study results in a more complete grasp of Immunology. His Clinical trial research is multidisciplinary, incorporating elements of T cell and Chimeric Antigen Receptor T-Cell Therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan;Nicholas McGranahan;Andrew J. S. Furness;Rachel Rosenthal;Sofie Ramskov.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R. Simpson;Fubin Li;Welby Montalvo-Ortiz;Manuel A. Sepulveda.
Journal of Experimental Medicine (2013)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh;Nicolai J. Birkbak;Nicolai J. Birkbak;Gareth A. Wilson;Gareth A. Wilson;Mariam Jamal-Hanjani.
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee;Bianca D. Santomasso;Frederick L. Locke;Armin Ghobadi.
Biology of Blood and Marrow Transplantation (2019)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
Karl S. Peggs;Sergio A. Quezada;Cynthia A. Chambers;Alan J. Korman.
Journal of Experimental Medicine (2009)
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
Sergio A. Quezada;Tyler R. Simpson;Karl S. Peggs;Taha Merghoub.
Journal of Experimental Medicine (2010)
Checkpoint blockade in cancer immunotherapy
Alan J. Korman;Karl S. Peggs;James P. Allison.
Advances in Immunology (2006)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Sergio A. Quezada;Karl S. Peggs;Michael A. Curran;James P. Allison.
Journal of Clinical Investigation (2006)
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Waseem Qasim;Hong Zhan;Sujith Samarasinghe;Stuart Adams.
Science Translational Medicine (2017)
Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
Laurent Poirot;Brian Philip;Cécile Schiffer-Mannioui;Diane Le Clerre.
Cancer Research (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: